Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

被引：190

作者：

Berman, Horacio ^{[1
]}

Rodriguez-Pinto, Ignasi ^{[1
]}

Cervera, Ricard ^{[1
]}

Morel, Nathalie ^{[2
,5
]}

Costedoat-Chalumeau, Nathalie ^{[2
,5
]}

Erkan, Doruk ^{[3
]}

Shoenfeld, Yehuda ^{[4
]}

Espinosa, Gerard ^{[1
]}

机构：

[1] Hosp Clin Barcelona, IDIBAPS, Dept Autoimmune Dis, E-08036 Barcelona, Catalonia, Spain

[2] Univ Paris 05, Paris, France

[3] Cornell Univ, Hosp Special Surg, Weill Med Coll, Barbara Volcker Ctr Women & Rheumat Dis, New York, NY 10021 USA

[4] Chaim Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel

[5] Hop Cochin, AP HP, Serv Med Interne, Ctr Malad Rares, F-75674 Paris, France

来源：

AUTOIMMUNITY REVIEWS | 2013年 / 12卷 / 11期

关键词：

Catastrophic antiphospholipid syndrome; Refractory; Rituximab; Anti-CD20; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC LUPUS ERYTHAEMATOSUS; CELL DEPLETION THERAPY; CLASSIFICATION CRITERIA; MANAGEMENT;

D O I：

10.1016/j.autrev.2013.05.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the Catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：1085 / 1090

页数：6

共 26 条

[1]

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].

Asherson, RA ;

Cervera, R ;

de Groot, PG ;

Erkan, D ;

Boffa, MC ;

Piette, JC ;

Khamashta, MA ;

Shoenfeld, Y .

LUPUS, 2003, 12 (07) :530-534

[2]

Relapsing catastrophic antiphospholipid syndrome: Report of three cases [J].

Asherson, Ronald A. ;

Espinosa, Gerard ;

Menahem, Solomon ;

Yinh, Janet ;

Bucciarelli, Silvia ;

Bosch, Xavier ;

Cervera, Ricard .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2008, 37 (06) :366-372

[3]

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis [J].

Buch, Maya H. ;

Smolen, Josef S. ;

Betteridge, Neil ;

Breedveld, Ferdinand C. ;

Burmester, Gerd ;

Doerner, Thomas ;

Ferraccioli, Gianfranco ;

Gottenberg, Jacques-Eric ;

Isaacs, John ;

Kvien, Tore K. ;

Mariette, Xavier ;

Martin-Mola, Emilio ;

Pavelka, Karel ;

Tak, Paul P. ;

van der Heijde, Desiree ;

van Vollenhoven, Ronald F. ;

Emery, Paul .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :909-920

[4]

Recurrence of Cutaneous Necrosis in an Infant with Probable Catastrophic Antiphospholipid Syndrome [J].

Camacho-Lovillo, Soledad ;

Bernabeu-Wittel, Jose ;

Iglesias-Jimenez, Estibaliz ;

Falcon-Neyra, Doloresm ;

Neth, Olaf .

PEDIATRIC DERMATOLOGY, 2013, 30 (04) :E63-E64

[5]

B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response [J].

Cambridge, G. ;

Isenberg, D. A. ;

Edwards, J. C. W. ;

Leandro, M. J. ;

Migone, T-S ;

Teodorescu, M. ;

Stohl, W. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :1011-1016

[6]

A Pilot Open-Label Phase II Trial of Rituximab for Non-Criteria Manifestations of Antiphospholipid Syndrome [J].

Erkan, Doruk ;

Vega, JoAnn ;

Ramon, Glendalee ;

Kozora, Elizabeth ;

Lockshin, Michael D. .

ARTHRITIS AND RHEUMATISM, 2013, 65 (02) :464-471

[7]

Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms [J].

Erkan, Doruk ;

Espinosa, Gerard ;

Cervera, Ricard .

AUTOIMMUNITY REVIEWS, 2010, 10 (02) :74-79

[8]

Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature [J].

Erre, G. L. ;

Pardini, S. ;

Faedda, R. ;

Passiu, G. .

LUPUS, 2008, 17 (01) :50-55

[9]

Espinosa G, 2007, J RHEUMATOL, V34, P923

[10]

Management of refractory cases of catastrophic antiphospholipid syndrome [J].

Espinosa, Gerard ;

Berman, Horacio ;

Cervera, Ricard .

AUTOIMMUNITY REVIEWS, 2011, 10 (11) :664-668

← 1 2 3 →